Efficacy and safety of oral minoxidil in female androgenetic alopecia.
alopecia
hair disorder
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
27
07
2020
revised:
12
08
2020
accepted:
18
08
2020
pubmed:
28
8
2020
medline:
15
5
2021
entrez:
28
8
2020
Statut:
ppublish
Résumé
Oral minoxidil (OM) has been reported to be effective for androgenetic alopecia (AGA). In this retrospective study, we share our experience of using OM for >24 weeks in 12 patients with female AGA (Ludwig scale I-3-III). Twelve women (aged 18-66 years; mean age 36.66 ± 18.79 years) with AGA (Ludwig scale I-3-III) were recruited. The starting dose of minoxidil was 0.50 mg daily; at 3 months, the dose was increased to 1.50 to 2 mg daily. Efficacy outcome measures were evaluated at baseline and after 24 weeks and included global clinical photography, quantitative digital videotrichoscopic assessment and quality-of-life evaluation. An overall improvement of 38% and 23% in hair density in the frontal and vertex area, respectively, was observed after 24 weeks. The quantitative digital videotrichoscopic evaluation highlighted a statistically significant improvement in the frontal area of the total average hair density and of the total number of hairs per unit area at 24 weeks (131.47 ± 36.11 vs 181.40 ± 57.38; P = .025 and 118.72 ± 32.61 vs 163.81 ± 51.82; P = .025, respectively). In conclusion, OM was effective and had an acceptable safety profile in treating female AGA. The low number of patients and retrospective design of this study are limitations.
Substances chimiques
Minoxidil
5965120SH1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14234Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Sinclair R, Trindade de Carvalho L, Ismail FF, Meah N. Treatment of male and female pattern hair loss with sublingual minoxidil: a retrospective case-series of 64 patients. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16616.
Ramos PM, Sinclair RD, Kasprzak M, Miot HA. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: a randomised clinical trial. J Am Acad Dermatol. 2020;82(1):252-253. https://doi.org/10.1016/j.jaad.2019.08.060.
Jha A, Sonthalia S, Zeeshan MD, Vinay K. Efficacy and safety of very low dose oral minoxidil 1.25mg in male androgenetic alopecia. J Am Acad Dermatol. 2020:S0190-9622(20)31005-7. https://doi.org/10.1016/j.jaad.2020.05.129.
Gomolin A, Litvinov IV, Netchiporouk E. Oral minoxidil: a possible new therapy for androgenetic alopecia. J Cutan Med Surg. 2020;24(1):88-89. https://doi.org/10.1177/1203475419879887.
Sinclair R, Patel M, Dawson TL Jr, et al. Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. Br J Dermatol. 2011;165(suppl 3):12-18. https://doi.org/10.1111/j.1365-2133.2011.10630.x.
Pirmez R, Salas-Callo CI. Very-low-dose oral minoxidil in male androgenetic alopecia: a study with quantitative trichoscopic documentation. J Am Acad Dermatol. 2020;82:e21-e22.